MEDIQON Group AG

Financial performance has remained strong, with revenue growing from $0.00 in Q4 2017 to $50.02M in Q2 2024. Gross profit continued to perform well, with margins at 14% in the latest quarter. Operating income reached -$4.95M in Q2 2024, holding a steady -10% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $7.05M. Net income dropped to -$4.48M, keeping EPS at -$0.23. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.